Medrx Co., Ltd. (JP:4586)
:4586
Want to see JP:4586 full AI Analyst Report?
4586 Stock Chart & Stats
¥113.00
¥2.00(2.50%)
At close: 4:00 PM EST
¥113.00
¥2.00(2.50%)
Day’s Range― - ―
52-Week Range¥58.00 - ¥225.00
Previous CloseN/A
Volume596.00K
Average Volume (3M)2.57M
Market Cap
¥4.69B
Enterprise Value¥2.99B
Total Cash (Recent Filing)¥1.67B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.53
Shares Outstanding59,365,100
10 Day Avg. Volume1,116,360
30 Day Avg. Volume2,574,156
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)2.83
Price to Sales (P/S)45.31
P/FCF Ratio-5.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margins & 2025 Revenue ReboundVery high gross margins (about 85–90%) and a sharp 2025 revenue rebound indicate strong core product economics and improving demand. Over a multi-quarter horizon this supports scalable gross profit generation, giving the company room to invest in commercialization or R&D if operating costs are controlled.
Zero Reported DebtA debt-free balance sheet materially reduces near-term solvency risk and interest burden, preserving strategic optionality. With no scheduled debt service the firm has flexibility to raise capital on favorable terms or prioritize investments, which is valuable while it works to stabilize operations.
Lean Workforce / Asset-light SetupA very small employee base suggests a lean, potentially asset-light business model common in specialty/generic drug developers. This can enable lower fixed overhead, faster scaling per incremental revenue, and more efficient capital deployment if commercial launches translate into sustained sales.
Bears Say
Chronic Negative Operating & Free Cash FlowConsistent negative operating and free cash flow (roughly -0.8B to -1.1B) shows the business is not self-funding and will likely need external capital to sustain operations. Over months this raises dilution and execution risk if financing windows narrow or costs cannot be reined in.
Deep, Persistent Net Losses And Negative ROEVery large operating and net losses with negative ROE indicate the company is destroying shareholder value rather than creating it. If losses persist the equity base erodes, limiting ability to fund growth internally and making sustained profitability a high hurdle without structural cost cuts or material revenue scaling.
Highly Volatile Revenue TrendVolatile top-line (Fundamentals show ~-50% revenue growth historically before a rebound) signals an uncertain revenue base and inconsistent market traction. For a drug manufacturer, this complicates capacity planning, R&D prioritization and makes margin recovery dependent on sustaining the recent rebound across multiple quarters.
4586 FAQ
What was Medrx Co., Ltd.’s price range in the past 12 months?
Medrx Co., Ltd. lowest stock price was ¥58.00 and its highest was ¥225.00 in the past 12 months.
What is Medrx Co., Ltd.’s market cap?
Medrx Co., Ltd.’s market cap is ¥4.69B.
When is Medrx Co., Ltd.’s upcoming earnings report date?
Medrx Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is tomorrow.
How were Medrx Co., Ltd.’s earnings last quarter?
Medrx Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥2.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.6.
Is Medrx Co., Ltd. overvalued?
According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued.
Does Medrx Co., Ltd. pay dividends?
Medrx Co., Ltd. does not currently pay dividends.
What is Medrx Co., Ltd.’s EPS estimate?
Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medrx Co., Ltd. have?
Medrx Co., Ltd. has 59,365,100 shares outstanding.
What happened to Medrx Co., Ltd.’s price movement after its last earnings report?
Medrx Co., Ltd. reported an EPS of -¥2.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.885%.
Which hedge fund is a major shareholder of Medrx Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4586
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medrx Co., Ltd.
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―